[1]赵兴忠,赵新国.康复新联合胸腺五肽治疗肺结核患者的效果及对血清CXCL-10、FIB水平的影响分析[J].徐州医科大学学报,2020,40(07):505-508.
 Effect of Kangkangxin combined with thymicpentapeptide on pulmonary tuberculosis and its effect on serum CXCL-10FIB level[J].Journal of Xuzhou Medical University,2020,40(07):505-508.
点击复制

康复新联合胸腺五肽治疗肺结核患者的效果及对血清CXCL-10、FIB水平的影响分析()
分享到:

《徐州医科大学学报》[ISSN:2096-3882/CN:32-1875/R]

卷:
40
期数:
2020年07期
页码:
505-508
栏目:
出版日期:
2020-07-30

文章信息/Info

Title:
Effect of Kangkangxin combined with thymicpentapeptide on pulmonary tuberculosis and its effect on serum CXCL-10FIB level
作者:
赵兴忠赵新国
分类号:
508
文献标志码:
A
摘要:
目的:将康复新液联合胸腺五肽用于肺结核患者的治疗,观察其临床疗效,及其对血清中CXCL-10、FIB水平的影响。方法:选取2015年4月-2017年4月于我院治疗的TB-PCR阳性或痰菌涂片阳性的初治肺结核患者140例,随机分为对照组(n=70例)和研究组(n=70例)。在治疗的最初两个月,研究组患者给予胸腺肽肠溶片+康复新液+利福平+异烟肼+乙胺丁醇+吡嗪酰胺;对照组给予利福平+异烟肼+乙胺丁醇+吡嗪酰胺。两个月后,研究组与对照组均给予利福平+异烟肼治疗四个月。观察两组患者的临床疗效及治疗过程中的不良反应发生率。比较两组患者治疗前后免疫功能指标(CD8+、CD4+、CD3+和CD4+/CD8+)及CXCL-10、FIB水平。结果:研究组的临床有效率为88.57%,对照组的临床有效率为75.71%,研究组的临床有效率明显高于对照组(P<0.05)。两组患者不良反应发生率无明显差异(P>0.05)。治疗前,两组患者CD8+、CD4+、CD3+、CD4+/CD8+、CXCL-10、FIB水平无明显差异(P>0.05)。治疗后,两组患者的CXCL-10、FIB、CD8+均明显下降(P<0.05),且研究组明显低于对照组(P<0.05);两组患者CD4+、CD3+、CD4+/CD8+均明显升高(P<0.05),且研究组明显高于对照组(P<0.05)。结论:康复新液联合胸腺五肽治疗肺结核,具有较好的临床疗效,可显著降低患者的炎症反应,提高患者的免疫功能,且安全性高,可在临床上推广应用。
Abstract:
Objective:The treatment of Pulmonary Tuberculosis patients with the combination of KangfengXin liquid and thymus pentapeptide.To observe the clinical curative effect and its effect on serum CXCL-10、FIB level.Methods:From April 2015 to April 2017, 140 patients with TB-PCR positive or sputum smear positive pulmonary tuberculosis treated in our hospital were selected.Randomly divided into control group (n = 70) and study group (n = 70).During the first two months of treatment, patients in the study group were given rifampicin, isoniazid, ethambutylamine, pyrazinamide, a new solution for the rehabilitation of thymosin enteric-coated tablets.The control group was given rifampicin isoniazid ethambutylaminepyrazinamide.Two months later, the study group and the control group were treated with rifampicin isoniazid for 4 months.To observe the clinical curative effect and the incidence of adverse reaction in the course of treatment.The indexes of immune function (CD8+, CD4+, CD3+ and CD4+/CD8+), CXCL-10 and FIB levels were compared between the two groups before and after treatment. Results:The clinical effective rate was 88.57 in the study group and 75.71 in the control group.The clinical effective rate of the study group was significantly higher than that of the control group (P < 0.05).After treatment, CXCL-10、FIB、CD8+ decreased significantly in both groups (P < 0.05).The study group was significantly lower than the control group (P < 0.05).The CD4+、CD3+、CD4+/CD8+ was significantly increased in both groups (P < 0.05), and was significantly higher in the study group than that in the control group (P < 0.05). Conclusion:The combination of KangfengXin liquid and thymus pentapeptide in the treatment of pulmonary tuberculosis has a good clinical effect, can significantly reduce the inflammatory reaction of patients, improve the immune function of patients, and high safety, can be popularized in clinical application
更新日期/Last Update: 2020-07-29